Cancer-related cognitive impairment (CRCI) is commonly reported postchemotherapy in adults with solid tumours. Hodgkin lymphoma (HL) mostly affects young adults. Data regarding CRCI in HL survivors (HLS) are scarce. The current study aimed to objectively assess CRCI incidence and characteristics in HLS. HLS, who completed first-line (chemotherapy AE radiation) therapy and remained in complete remission for 6 months to 5 years from therapy end, were evaluated. Age-and education-matched healthy individuals served as controls (n = 14). Test results were compared to population norms and healthy controls. Study participants completed self-reported questionnaires evaluating fatigue, depression, anxiety, quality of life and cognitive function. Subjects underwent neurocognitive evaluation, assessing processing speed, memory, attention, executive functions and intelligence domains. The present study included 51 HLS with a median age of 28 years, mean education of 14Á5 AE 2Á5 years. Complaints related to cognitive deterioration and fatigue were significantly more severe and frequent in HLS compared to healthy controls. Objective neurocognitive evaluation demonstrated that 30% of HLS were impaired in ≥2 cognitive domains. In conclusion, the present study demonstrates that fatigue and cognitive impairment, predominantly in executive functions and memory, constitute frequent and alarming findings in HLS. These adverse effects can persist and exert an impact on all aspects of life.
Hodgkin lymphoma (HL) is a malignant tumour, occurring most frequently between the ages of 20 and 35 years, with a median of 33 years (Johnson et al, 2016) . Over 8200 new cases of HL are diagnosed annually in the USA, where there are currently over 177 000 HL survivors (HLS) (Howlader et al, 2014; Hoppe et al, 2017) . The HL incidence in Israel is among the highest in the world (Levine et al, 2017) . The use of advanced staging techniques and successful treatment methods has resulted in high long-term survival rates, and the majority of patients will stay in complete remission. The accepted treatment options are systemic chemotherapy with or without radiotherapy, providing a 5-year progression-free survival (PFS) of 79-92% (Dann, 2012; Engert et al, 2012; Johnson et al, 2016) . The young patient age and improved prognosis result in a continuously growing population of HLS, who are at risk of long-term chemo/radio therapy toxicity (Straus, 2011) . Frequent complaints among HLS include persistent fatigue and changes in cognitive functions (Joly et al, 1996; Krull et al, 2012; Behringer et al, 2016) . Cancerrelated cognitive impairment (CRCI) is a commonly reported adverse effect of various malignancies and their therapies among adult survivors (Wefel et al, 2015) . CRCI is usually characterized by diminution of memory, attention, executive functioning and processing speed (Ahles & Saykin, 2007; Argyriou et al, 2011; Williams et al, 2016) . The majority of CRCI studies were performed on breast cancer patients, while several small-size studies incorporated patients with prostate, colorectal, or haematological cancers (Wefel et al, 2015) . Furthermore, as these malignancies primarily affect older adults, they commonly form the target population in CRCI studies. However, HL often develops in young adults, who have a long-life expectancy and in whom persistent fatigue and impaired cognition may have a dramatic impact on the quality of life, affecting their working and learning capacities and multiple aspects of social life. Yet, despite such insidious implications, the role of CRCI in HL is not fully elucidated. The current study aimed to assess the incidence and characteristics of CRCI in HLS.
Methods

Participants
Patients, aged 18-50 years, diagnosed with HL, who completed first-line therapy with either ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) or escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) protocols with or without radiotherapy and were in complete remission (CR) for 6 months to 5 years from the end of therapy were included in this study. Study subjects had to be fluent in Hebrew and have 12 or more years of education. All the patients with the above characteristics were recruited at the Rambam Department of Haematology and Bone Marrow Transplantation using the cross-sectional approach. Patient responsiveness was high. Only four patients were excluded for the following reasons: three because of a history of a prior psychiatric diagnosis [post-trauma stress disorder, obsessive-compulsive disorder, depression] and one patient had only 10 years of education. Age-and education-matched healthy controls (HC) were included in the present study. The HC were recruited from family members, partners or close friends of the patients, and several were random unrelated individuals with the same background as the patients in terms of language, education and age.
Procedures
The study was approved by the Institutional Review Board (IRB) of the Rambam Health Care Campus (approval #RMB 0420-15) and all participants signed the informed consent form. Participants underwent an enrolment interview, covering the following issues: general medical history, pre-diagnosis and post-recovery cognitive functioning, learning abilities, school grades and family history. Relevant data related to HL parameters and treatment were collected.
All participants completed self-reported outcome questionnaires, which included:
1 The Functional Assessment of Cancer Therapy-Cognitive Function (FACT-cog). This questionnaire evaluates the subject's perceived memory, attention, concentration, language and thinking abilities and incorporates four subscales: Perceived Cognitive Impairments (cog-PCI), score range 0-72; Perceived Cognitive Abilities (cog-PCA), score range 0-28; Impact on Quality of Life (cog-QOL), score range 0-16 and Comments from Others subscale (cog-OTH) score range 0-16. Items CogPMT1 ("I am able to shift back and forth between two activities that require thinking") and CogPMT2 ("I am able to keep track of what I am doing, even if I am interrupted") were scored independently. Each item is rated on a 5-point Likert scale from 0 (never) to 4 (several times a day). Higher scores on the individual sub-scales correlate with a better cognitive function (Wagner et al, 2009 (Beck et al, 1996) . 5 The Hamilton Anxiety Rating Scale (HAM) is a questionnaire used to rate the severity of anxiety. The HAM consists of 14 items, designed to measure psychic anxiety, mental agitation, psychological distress and somatic anxiety. Higher total scores indicate more severe anxiety symptoms. A score of ≥25 indicates moderate to severe anxiety (Hamilton, 1959) .
Neuropsychological evaluations were completed by a trained research assistant under the supervision of a clinical neuropsychologist. The following cognitive domains were evaluated: general intelligence, attention, processing speed, memory and learning and executive functions. The test battery included: the California verbal learning test (CVLT) (Delis et al, 2000) , the digit span subtest (WAIS-III-R) (Wechsler, 1997) , the trail making tests (TMT) A + B (Tombaugh, 2004) , and the Stroop (Stroop, 1935; Scarpina & Tagini, 2017) and Raven progressive matrices tests (Raven, 2003) and the following subtests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL), Stockings of Cambridge (SOC), Intra-Extra Dimensional Set Shift (IED), Reaction Time (RTI) and Rapid Visual Information Processing (RVP) (Robbins et al, 1994 (Robbins et al, , 1998 . Given that each neuropsychological test measures multiple parameters, significant representative Table I .
Raw test results were converted and presented in demographically corrected Z scores (according to normative data, based on age, education and gender, as presented in the test manuals). A test result was considered to be impaired when a subject scored ≤1Á5 standard deviations (SD) below the expected norm. A domain was regarded impaired when a subject scored ≤1Á5 SD below the expected norm in at least one significant representative parameter belonging to a neuropsychological test.
Statistical analyses
All statistical analyses were conducted with SPSS version 21 (IBM Corp., Armonk, NY, USA). Descriptive statistics were calculated for demographic, sociodemographic, clinical, psychological and treatment characteristics. Performance in neurocognitive evaluation was transformed to age-adjusted z scores using normative data. Percentile and T-score were converted to z scores using the psychometric conversion table. One-sample t tests were conducted to identify the measures that differed from an expected z = 0. Mann Whitney nonparametric tests were performed to compare HLS and HC scores, within neurocognitive evaluations and selfreported questionnaire mean scores. This test was also used to identify an association between neurocognitive evaluation and other variables (e.g., demographic, emotional symptoms, cognitive deterioration, fatigue and quality of life). v 2 tests for categorical variables were conducted to compare HLS and HC for all parameters and outcomes. Logistic regression analysis was used to examine the influence of all variables on neurocognitive outcomes. Two-tailed P values of 0Á05 or less were considered statistically significant.
Results
Fifty-one HLS with a median age of 28 years (range 19-48), mean education of 14Á5 AE 2Á5 years, median time from the end-of-therapy positron emission tomography-computed tomography (PET-CT) of 24Á7 months (range 4-60), and 14 HC with a median age of 28Á5 years (range 20-38) and mean education of 14Á7 AE 2Á2 years were included in the present study. No significant differences in demographic characteristics between HLS and HC participants were noted; demographic characteristics and treatment history are presented in Table II .
Self-reported outcomes
HLS reported the subjective experience of fatigue and cognitive impairment; complaints related to cognitive deterioration (FACT-Cog) and fatigue were reported more frequently and were significantly more severe in HLS compared to HC. Severe depression and anxiety were infrequently reported by HLS (Table III) .
Neurocognitive evaluations
HLS scored within normative data on measures of general intelligence. On measures of attention, the scores of HLS were within the normal range on the digit span subtest; nonetheless, total mean scores were in the lower range (P < 0Á049). Twelve percent of HLS scored within the impaired range on the CANTAB-RVP A' test. On tests evaluating learning and memory, 22% of HLS scored within the impaired range in the first trial of list A (P < 0Á025), 10% on the short and 14% on the delayed recall subtests of the CVLT and 4% had significantly more errors on the CAN-TAB-PAL. On tests evaluating executive function, 27% of HLS scored within the impaired range on TMT-B (P < 0Á001), 10% on the CANTAB-SOC, 14% on the CAN-TAB-IED and 2% on the Stroop interference measures (P < 0Á006). On processing speed measures, 16% of HLS scored within the impaired range on TMT-A (P < 0Á001) and 6% on the CANTAB-RTI (P < 0Á001). HC scored within the normal range on all significant representative test-parameters apart from one participant (7%) whose score was within the impaired range in the first trial of CVLT, list A (Table I ). All tests and sub-tests performed are listed in Table SI . Overall, HLS tended to score within the impaired range in ≥1 significant representative test parameters: 41% on measures of executive functions, 28% on measures of learning and memory, 22% on processing speed and 12% on attention.
Thirty percent of HLS had ≥2 impaired cognitive domains on the neurocognitive evaluation. The most frequently affected domain was that of executive functions.
Among the participants of the present study, self-reported complaints and objective cognitive measures were similar in HLS evaluated at 6 months following the end of therapy and in those evaluated up to 5 years post-treatment.
No association was found between fatigue, anxiety, depression and neurocognitive performance.
Likewise, no association was revealed between disease parameters, treatment protocols and neurocognitive performance. Nonetheless, only 13% of HLS who received 4 cycles of the ABVD regimen were impaired on ≥2 significant representative parameters, whereas amongst those who received 6 ABVD cycles and or escalated BEACOPP 33% were similarly affected (P = 0Á276). No significant differences in any of the evaluated parameters were observed between HLS undergoing chemotherapy and radiotherapy.
Fewer years of education tended to be more frequently associated with impairment in ≥2 significant representative parameters, i.e., 35% of HLS with 12 years of education vs. 11% of HLS with ≥17 years of education (P < 0Á208) exhibited cognitive impairment. FACT-cog PMT2 was significantly associated with the cognitive performance. Subjects who perceived significant impairment (mean 1Á3 AE 1Á5) were impaired on ≥2 significant representative parameters, whereas those who perceived their cognitive abilities as healthier (mean 2Á1 AE 1Á2) were impaired on ≤1 significant representative parameter only (P < 0Á034).
On the Raven progressive matrices test, a non-verbal estimate of intelligence, the lower was the score the higher was the likelihood of cognitive impairment. Sixty-two percent of HLS who scored below the 25th percentile (within low average) were impaired on ≥2 significant representative parameters, compared to none of those who scored above the 76th percentile (high average). Similarly, HLS who were impaired on ≥2 significant representative parameters scored significantly lower (mean 34 AE 22) than those who were impaired on ≤1 significant representative parameter (mean 64 AE 25) (P < 0Á001).
Discussion
The past decade has witnessed important advances in anticancer therapies resulting in increased patient survival. Cancer survivors frequently report the experience of residual persistent fatigue and cognitive deterioration. In objective neuropsychological evaluations, various degrees of CRCI have been previously reported in up to 60% of adult cancer survivors; this is particularly meaningful as about 35% of such individuals may live up to 20 years after treatment (Koppelmans et al, 2012; Wefel et al, 2015) . The aetiology of CRCI has not been fully elucidated. It is widely assumed that conventional chemotherapies do not cross the brain blood barrier (BBB). However, recent data reveal that agents such as doxorubicin, cyclophosphamide and cisplatin, do, in fact, cross the BBB, and thus may have effects on the decreased mitochondrial function, increase the oxidative stress and lead to morphological changes in the brain and consequently to neurophysiological dysfunction (Ahles & Saykin, 2007; Kitamura et al, 2015; Lomeli et al, 2017) . Our findings revealed that HLS who received fewer chemotherapy cycles had better neurocognitive performance and were consistent with previously published data (Baudino et al, 2012) , supporting these hypotheses.
The majority of previous investigations on CRCI were conducted in adult breast cancer patients, while some small studies included patients with other solid tumours (colorectal, testicular, prostate, ovarian and lymphoma) (Wefel et al, 2015) , and a single study objectively evaluated adult survivors of childhood HL ≥15 years post-therapy (Krull et al, 2012) . However, data on potential CRCI in adolescents and young adults aged 15-39 years (Chan et al, 2016) during treatment are presently lacking. To the best of our knowledge, the current study is the first to objectively evaluate cognitive impairment and the effects of HL and its therapy on young adult HLS. HL is a disease affecting young adults in their prime cognitive period, when they are supposed to be receiving education, building up careers and starting families. The high rate of successful outcomes reported in HL, with about 75-90% of survivors anticipated to remain disease-free and have a long-life expectancy (Dann, 2012; Engert et al, 2012; Johnson et al, 2016) , emphasizes the need for measures aiming to diminish the detrimental effect of CRCI on the quality of life in these patients. The fact that 30% of our patients have exhibited impairment in ≥2 out of 4 cognitive domains reflects the importance of such investigations.
The results of the present study demonstrate that objective cognitive impairment is common among young HLS, with the executive function domain being most frequently damaged. Similar findings have been recently reported in paediatric acute lymphoblastic lymphoma survivors (Krull et al, 2013) , childhood HLS (Krull et al, 2012) and haematopoietic cell transplant (HCT) recipients (Sharafeldin et al, 2018) .
Thirty-seven percent of our patients reported the feeling of considerable and persistent fatigue (Table III) . This is in line with previous studies where fatigue has been identified as a major residual complaint following recovery from HL and the effects of therapy (Straus, 2011; Behringer et al, 2016) . Remarkably, in our study, the subjective experience of fatigue has not been associated with the objectively measured neurocognitive performance, suggesting that the cognitive impairment, experienced by about 40% of study participants, cannot be attributed to fatigue. Another study, evaluating quality of life in HLS 10 years post-therapy, reported more complaints of cognitive dysfunction and fatigue among these individuals compared to controls (Joly et al, 1996) . Notably, unlike our results, these findings were based on subjective evaluation only.
The term "executive functions" refers to mental activities that involve the control of cognitive processes (e.g., planning, energizing, switching, inhibiting and monitoring) and enable behavioural and emotional self-regulatory functions (Stuss & Alexander, 2007) . Executive functions are mediated by neural networks involving the frontal lobes, predominantly the prefrontal cortex. Disruption of these functions can have deleterious effects on all areas of life, including vocational, academic and social activities.
The feelings of an impaired ability to shift back and forth between two activities that require thinking, and a decreased ability to keep track of what is being done, i.e., to concentrate (FACT-cog PMT2), reflect an impairment in the domain of executive functions. This has been the only subjective cognitive complaint, correlating with objective impairment on neurocognitive measures. No association has been found between other cognitive complaints and actual performance on specific cognitive tests. This may point either to oversensitivity of HLS to their current cognitive abilities or to the insufficient sensitivity of our tests to identify residual acquired impairments.
In the present study, diminished executive function domain has been revealed in 41% of HLS; this is in line with recent studies stating that the prefrontal cortex is significantly affected by cancer treatment, such as radiation and chemotherapy (Kovalchuk, 2017) .The second most frequently affected domain appears to be memory and learning. Given that this domain is extensively dependent on an intact hippocampal function, this brain area can be considered an additional target adversely affected by chemotherapy (Kovalchuk, 2017) . Previously, CRCI was thought to be related to emotional factors, such as depression or anxiety or other long-term cancer effects, such as fatigue (Ahles & Saykin, 2007) . However, similar to other reports (Vardy et al, 2015; O'Farrell et al, 2016) , we have found no association between the experienced, subjective complaints regarding anxiety and depression and the objective performance on the neurocognitive tests.
We have documented a significant positive correlation between measures of general intelligence abilities (the RAVEN test) and objective cognitive performance. Likewise, fewer years of education tended to be associated with worse neurocognitive performance. Comparable findings were reported in childhood HL survivors (Krull et al, 2012) and in testicular cancer survivors (Amidi et al, 2015) of the age similar to that of our HLS. This association between educational attainment/high intellectual capacities and resistance to the effects of disease and therapy may reflect the notion known as "cognitive reserve". The term "cognitive reserve" was introduced to describe the discrepancy between the clinical manifestations and the pathology in Alzheimer disease, scribed to describe the mind's resistance to damage of the brain (Katzman et al, 1988) . Cognitive reserve is probably influenced by genetic as well as environmental factors, emphasizing that protective factors acquired prior to disease onset, e.g., education, lifestyle and socio-economic status, may ameliorate the functional disabilities associated with the disease and its treatment. In addition, these findings suggest that it might be possible to enhance the resistance to CRCI by specific training programs and/or therapies.
Our study has several limitations. We have evaluated HLS following the end of therapy. The lack of pre-treatment assessment restricts our validation of outcome, as well as the effect of HL and its treatment on CRCI. The relatively small sample size has restricted the results of multivariate analysis, including such variables as disease stages, treatment groups, symptoms and their influence on CRCI.
In conclusion, the present study demonstrates that fatigue and cognitive impairment, predominantly deterioration of executive functions and memory, constitute frequent and alarming complaints in HLS. These adverse effects can persist and exert an impact on all aspects of life. CRCI and its modifiers have to be taken into consideration at the stage of planning therapy in HL patients. Further research including a longitudinal large cohort is warranted to assess CRCI aetiology and associated factors in this patient population prior to and post-therapy. The current study emphasizes the need for post-therapy support and guidance to overcome CRCI in HLS.
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